(Loss) Gain from Sale of Priority Review Voucher (PRV)	12 Months Ended
Dec. 31, 2023
(Loss) Gain from Sale of Priority Review Voucher (PRV)
(Loss) Gain from Sale of Priority Review Voucher (PRV)	13. (Loss) Gain from Sale of Priority Review Voucher (PRV) On July 13, 2022, we entered into an asset purchase agreement (Purchase Agreement) with Novo Nordisk Inc. (Buyer), pursuant to which we agreed to sell our Priority Review Voucher (PRV) to Buyer. The United States Secretary of Health and Human Services, FDA, issued the PRV to us on March 18, 2022 in connection with the approval of the use of ZTALMY. Pursuant to the Purchase Agreement, Buyer agreed to pay us $110.0 million, payable in cash, upon the closing of the transaction which occurred in the third quarter of 2022. We recorded a one-time net gain from the sale of the PRV in the year ended December 31, 2022. In August 2022, we received a letter from Purdue in which Purdue claimed that it was owed $5.5 million by us from the sale of the PRV pursuant to the Purdue License Agreement. We responded to Purdue that we did not agree with their claim. In February 2024, following discussions with Purdue, we agreed to pay Purdue $4 million in respect of its claim. As of December 31, 2023, we have accrued a liability of $4.0 million, which will be paid to Purdue in two equal installments, the first on or before March 15, 2024, and the second on or before June 15, 2024. We recorded a one-time net loss of $4.0 million in the year ended December 31, 2023 related to this payment owed to Purdue in connection with the sale of the PRV.

(Loss) Gain from Sale of Priority Review Voucher (PRV)

12 Months Ended

Dec. 31, 2023

(Loss) Gain from Sale of Priority Review Voucher (PRV)

(Loss) Gain from Sale of Priority Review Voucher (PRV)

13. (Loss) Gain from Sale of Priority Review Voucher (PRV)

On July 13, 2022, we entered into an asset purchase agreement (Purchase Agreement) with Novo Nordisk Inc. (Buyer), pursuant to which we agreed to sell our Priority Review Voucher (PRV) to Buyer. The United States Secretary of Health and Human Services, FDA, issued the PRV to us on March 18, 2022 in connection with the approval of the use of ZTALMY. Pursuant to the Purchase Agreement, Buyer agreed to pay us $110.0 million, payable in cash, upon the closing of the transaction which occurred in the third quarter of 2022. We recorded a one-time net gain from the sale of the PRV in the year ended December 31, 2022.

In August 2022, we received a letter from Purdue in which Purdue claimed that it was owed $5.5 million by us from the sale of the PRV pursuant to the Purdue License Agreement. We responded to Purdue that we did not agree with their claim. In February 2024, following discussions with Purdue, we agreed to pay Purdue $4 million in respect of its claim. As of December 31, 2023, we have accrued a liability of $4.0 million, which will be paid to Purdue in two equal

installments, the first on or before March 15, 2024, and the second on or before June 15, 2024. We recorded a one-time net loss of $4.0 million in the year ended December 31, 2023 related to this payment owed to Purdue in connection with the sale of the PRV.